BCRX's Quality Score fell 1 point on Mon, Nov 2, to 3.
Follow BCRX's trial news. Pro members can get an alert when BioCryst Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 11% over the five sessions to Oct 30 while the S&P 500 fell 0.6%.
| Since its 2022 high | Down 57% |
| Latest filing | 10-Q, Aug 5 |
ReportReports Wednesday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -0.8% on average. Past reports ›
Thu Nov 12: American College of Allergy…Industry event · date confirmed.
After its last 4 reports it closed -0.8% on average, higher 2 of 4 times.
Director Amy E McKee sold 11,180 shares on May 18. 3 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
BCRX is #80 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 80 |
Share count against a year before: BCRX +21%, HALO -3.4%, KRYS +2.1%, TARS +2.4%.
Reports Wed Nov 4, before the open (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily due to costs associated with the navenibart ALPHA-ORBIT study following the acquisition of Astria in the first quarter of 2026.”
BCRX's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | $690M to $715M |
Sales grew 48% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 5.5% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | +4.7% | +0.6% | +14.6% |
| May 6, 2026 | -4.4% | -2.2% | -2.5% |
| Feb 26, 2026 | +8.5% | +4.6% | +13.5% |
Sales grew in six of the last seven years, to $875M in 2025. It turned a profit in 2025 after a loss in 2024.
One insider sold $100K across 1 filing in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BCRX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
“The pharmaceutical and biotechnology industries are intensely competitive.”
BCRX scores 3 today, which Breakaway calls Below Average. It is #80 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 11% over the five sessions to Oct 30 while the S&P 500 fell 0.6%. Shares: 21.5% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BCRX scores 3 today, which Breakaway calls Below Average (0 to 5). That is #80 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BCRX's 3.
One insider sold $100K across 1 filing in the last 6 months. No open-market buys on record. The newest is Amy E. McKee, Director, who sold $100K on May 18.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.